157 related articles for article (PubMed ID: 27769033)
1. Urea-containing peptide boronic acids as potent proteasome inhibitors.
Han LQ; Yuan X; Wu XY; Li RD; Xu B; Cheng Q; Liu ZM; Zhou TY; An HY; Wang X; Cheng TM; Ge ZM; Cui JR; Li RT
Eur J Med Chem; 2017 Jan; 125():925-939. PubMed ID: 27769033
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
4. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
5. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.
Han L; Wen Y; Li R; Xu B; Ge Z; Wang X; Cheng T; Cui J; Li R
Bioorg Med Chem; 2017 Aug; 25(15):4031-4044. PubMed ID: 28634039
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
10. Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors.
Zhuang R; Gao L; Lv X; Xi J; Sheng L; Zhao Y; He R; Hu X; Shao Y; Pan X; Liu S; Huang W; Zhou Y; Li J; Zhang J
Eur J Med Chem; 2017 Jan; 126():1056-1070. PubMed ID: 28027531
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
12. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
13. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Zhang J; Shen L; Wang J; Luo P; Hu Y
Med Chem; 2014; 10(1):38-45. PubMed ID: 23676009
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
16. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
17. Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
J Med Chem; 2014 Mar; 57(6):2726-35. PubMed ID: 24524217
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
Zhu Y; Zhu X; Wu G; Ma Y; Li Y; Zhao X; Yuan Y; Yang J; Yu S; Shao F; Li R; Ke Y; Lu A; Liu Z; Zhang L
J Med Chem; 2010 Mar; 53(5):1990-9. PubMed ID: 20158184
[TBL] [Abstract][Full Text] [Related]
19. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y
Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958
[TBL] [Abstract][Full Text] [Related]
20. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]